<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Drug Investig</journal-id><journal-id journal-id-type="iso-abbrev">Clin Drug Investig</journal-id><journal-title-group><journal-title>Clinical Drug Investigation</journal-title></journal-title-group><issn pub-type="ppub">1173-2563</issn><issn pub-type="epub">1179-1918</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26091744</article-id><article-id pub-id-type="pmc">4488495</article-id><article-id pub-id-type="publisher-id">300</article-id><article-id pub-id-type="doi">10.1007/s40261-015-0300-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Riedl</surname><given-names>Marc</given-names></name><address><phone>+1-858-6575350</phone><email>mriedl@ucsd.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, 8899 University Center Lane, Ste 230, San Diego, CA 92122 USA </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>35</volume><issue>7</issue><fpage>407</fpage><lpage>417</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>Hereditary angioedema (HAE), a rare autosomal dominant genetic disorder, is caused by a deficiency in functional C1 esterase inhibitor (C1-INH). This potentially life-threatening condition manifests as recurrent attacks of subcutaneous and submucosal swelling of the skin, gastrointestinal tract and larynx. The management of HAE includes treatment of acute episodes, short-term prophylaxis in preparation for exposure to known triggers and long-term prophylaxis to decrease the incidence and severity of HAE attacks. Four products are approved in the USA for the treatment of acute attacks of HAE, including one human plasma-derived C1-INH therapy, a recombinant human C1-INH product (rhC1-INH), a plasma kallikrein inhibitor and a bradykinin B2 receptor antagonist. In addition, one human plasma-derived C1-INH therapy and danazol are approved for prophylaxis of HAE attacks. rhC1-INH, extracted from the milk of transgenic rabbits, is a glycoprotein of 478 amino acids with an identical amino acid sequence to the endogenous human C1-INH protein. Population pharmacokinetic analysis of rhC1-INH supports an intravenous dosing strategy of 50&#x000a0;U/kg (maximum 4200&#x000a0;U). The safety and efficacy of rhC1-INH in the treatment of acute attacks in patients with HAE were demonstrated in three randomized, double-blind, placebo-controlled studies and two open-label extension studies. In a pilot prophylaxis study, weekly administration of rhC1-INH 50&#x000a0;U/kg for 8&#x000a0;weeks reduced the incidence of HAE attacks and was well tolerated. Administration of rhC1-INH has not been associated with the development of anti-drug antibodies or antibodies to anti-host-related impurities.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d30e161"><title>Key Points</title><p><table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Hereditary angioedema (HAE) is a potentially life-threatening autosomal dominant disorder caused by deficiency of functional C1 esterase inhibitor (C1-INH).</td></tr><tr><td align="left">Four products are approved for the treatment of acute HAE in the USA, including one human plasma-derived C1-INH therapy, a recombinant human C1-INH product (rhC1-INH), a plasma kallikrein inhibitor and a bradykinin B2 receptor antagonist. Another human plasma-derived C1-INH therapy and danazol are approved for HAE prophylaxis.</td></tr><tr><td align="left">In randomized, controlled trials and open-label extension studies, rhC1-INH has demonstrated efficacy and safety for the treatment of acute attacks of HAE, with preliminary data showing possible utility for long-term HAE prophylaxis.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Hereditary angioedema (HAE) is a rare autosomal dominant genetic disease caused by a quantitative or qualitative deficiency of C1 esterase inhibitor (C1-INH) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The disease is characterized by recurrent episodes (attacks) of subcutaneous and submucosal swelling involving the skin, gastrointestinal tract and larynx [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Swelling of the larynx can cause fatal asphyxiation [<xref ref-type="bibr" rid="CR2">2</xref>]. Although the frequency of attacks can vary considerably in untreated patients (every 7&#x02013;14&#x000a0;days on average), individual HAE attacks generally follow a predictable clinical course of symptoms developing gradually during the first 24&#x000a0;h and then subsiding during the subsequent 48&#x02013;72&#x000a0;h [<xref ref-type="bibr" rid="CR1">1</xref>]. The prevalence of HAE is unclear; however, it is estimated to affect 1 in 50,000&#x02013;100,000 individuals globally [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. The onset of symptoms typically begins during childhood; symptoms often worsen during puberty, and HAE attacks generally continue throughout the life of the patient [<xref ref-type="bibr" rid="CR1">1</xref>]. HAE episodes usually occur without a predictable trigger; however, attacks can be precipitated by minor surgical or dental procedures or trauma, infection and stress [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>C1-INH is a serine protease inhibitor, which directly or indirectly inhibits several proteases associated with HAE attacks (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. C1-INH is a major inhibitor of several complement proteases such as C1r and C1s [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] and contact proteases, including factor XIIa [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] and kallikrein [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], and a minor inhibitor of fibrinolytic proteases such as plasmin and factor XIa [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. In patients with HAE, uninhibited activation of the contact pathway due to insufficient levels of functional C1-INH results in unregulated cleavage of high molecular weight kininogen by kallikrein, leading to generation of excessive free bradykinin [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Bradykinin is a potent vasoactive peptide, which mediates increased capillary permeability and oedema [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. There are three subtypes of HAE, generally classified according to associated levels and functional activity of C1-INH [<xref ref-type="bibr" rid="CR1">1</xref>]. Type I is the most prevalent, accounting for ~85&#x000a0;% of cases, and is defined by a quantitative deficiency of C1-INH protein [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Type II HAE (~15&#x000a0;% of cases) is associated with normal levels of C1-INH but deficient functional C1-INH activity, as the protein does not function properly. HAE with normal C1-INH (historically referred to as type III) is a rare, largely oestrogen-dependent form of HAE, mostly affecting females; the quantitative and functional levels of C1-INH are normal but patients experience angioedema attacks [<xref ref-type="bibr" rid="CR1">1</xref>]; the pathophysiology of this HAE subtype is poorly understood.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Schematic representation of the pathways inhibited by C1 esterase inhibitor (C1-INH). C1-INH inhibits proteases in the complement, contact activation and fibrinolytic pathways. In hereditary angioedema, uninhibited activation of the contact pathway because of deficiency in functional C1-INH results in unregulated cleavage of high molecular weight kininogen by kallikrein, leading to generation of excessive free bradykinin, which is a potent vasoactive peptide. Proteolytic activities are indicated with <italic>green arrows</italic>, and steps inhibited by C1-INH are shown by <italic>red bars</italic>. From Zuraw [<xref ref-type="bibr" rid="CR1">1</xref>]. &#x000a9; 2008 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society [<xref ref-type="bibr" rid="CR1">1</xref>]</p></caption><graphic xlink:href="40261_2015_300_Fig1_HTML" id="MO1"/></fig></p><p>The management of HAE includes treatment of acute attacks, short-term or procedural prophylaxis (e.g. before dental procedures, minor surgery or endoscopy) and long-term prophylaxis to minimize the frequency and severity of recurrent attacks [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Until 2008, management of HAE in the USA was limited to the use of fresh frozen plasma, antifibrinolytic agents, synthetic attenuated androgens and supportive care. Six products are currently approved by the US Food and Drug Administration (FDA) for the acute treatment (<italic>n</italic>&#x000a0;=&#x000a0;4) or prophylaxis (<italic>n</italic>&#x000a0;=&#x000a0;2) of HAE (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. These products include three C1-INH replacement therapies (two human plasma-derived C1-INH preparations [Cinryze<sup>&#x000ae;</sup> (Shire ViroPharma Inc., Lexington, MA, USA) and Berinert<sup>&#x000ae;</sup> (CSL Behring GmbH, Marburg, Germany)] and one recombinant human C1-INH preparation [rhC1-INH]), a plasma kallikrein inhibitor (ecallantide), a bradykinin B2 receptor antagonist (icatibant) and a synthetic attenuated androgen (danazol). In Europe, human plasma-derived C1-INH products have been used for more than three decades for the treatment of acute HAE, and icatibant and rhC1-INH have been approved since 2008 and 2010, respectively [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. Although human plasma-derived C1-INH products have been available globally for many years, there are concerns, as with any plasma-derived product, about the potential risk of transmission of blood-borne pathogens, as well as supply issues [<xref ref-type="bibr" rid="CR27">27</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>US Food and Drug Administration (FDA)-approved agents for the treatment of hereditary angioedema (HAE) [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Generic name</th><th align="left">Brand name</th><th align="left">Description</th><th align="left">Mode of administration and dose</th><th align="left">Indication</th><th align="left">FDA approval</th></tr></thead><tbody><tr><td align="left">Danazol</td><td align="left">Formerly marketed as Danocrine<sup>&#x000ae;</sup> in the USA</td><td align="left">Synthetic attenuated androgen</td><td align="left">Oral<break/>Initial dosing 100&#x02013;200&#x000a0;mg daily. After favorable initial response (prevention), continuing dose should be minimized by decreasing dosage as tolerated based on clinical response and frequency of attacks</td><td align="left">Prevention of angioedema attacks of all types (cutaneous, abdominal, laryngeal) in males and females</td><td char="." align="char">1976</td></tr><tr><td align="left">C1 esterase inhibitor (human)</td><td align="left">Cinryze<sup>&#x000ae;</sup>
</td><td align="left">Plasma-derived C1 esterase inhibitor</td><td align="left">IV<break/>1000&#x000a0;U every 3 or 4&#x000a0;days<break/>Can be self-administered</td><td align="left">Routine prophylaxis against angioedema attacks in adolescents and adults with HAE</td><td char="." align="char">2008</td></tr><tr><td align="left">C1 esterase inhibitor (human)</td><td align="left">Berinert<sup>&#x000ae;</sup>
</td><td align="left">Plasma-derived C1 esterase inhibitor</td><td align="left">IV<break/>20&#x000a0;IU per kg body weight<break/>Can be self-administered</td><td align="left">Acute abdominal, facial or laryngeal attacks of HAE in adolescents (aged &#x02265;13&#x000a0;years) and adults</td><td char="." align="char">2009</td></tr><tr><td align="left">Ecallantide</td><td align="left">Kalbitor<sup>&#x000ae;</sup>
</td><td align="left">Plasma kallikrein inhibitor</td><td align="left">SC<break/>30&#x000a0;mg (3&#x000a0;&#x000d7;&#x000a0;10&#x000a0;mg injections); additional 30 mg within 24-h period<break/>Should be administered only by a healthcare provider</td><td align="left">Acute HAE attacks in patients aged &#x02265;12&#x000a0;years</td><td char="." align="char">2009</td></tr><tr><td align="left">Icatibant</td><td align="left">Firazyr<sup>&#x000ae;</sup>
</td><td align="left">Bradykinin B2 receptor antagonist</td><td align="left">SC<break/>30&#x000a0;mg abdominal injection every 6&#x000a0;h (maximum, 3 doses every 24&#x000a0;h)<break/>Can be self-administered</td><td align="left">Acute HAE attacks in adults (aged &#x02265;18&#x000a0;years)</td><td char="." align="char">2011</td></tr><tr><td align="left">C1 esterase inhibitor (human)</td><td align="left">Ruconest<sup>&#x000ae;</sup>
</td><td align="left">rhC1-INH</td><td align="left">IV<break/>50&#x000a0;IU/kg (&#x0003c;84&#x000a0;kg body weight) and 4200&#x000a0;IU (&#x02265;84&#x000a0;kg body weight); &#x02264;2 doses every 24&#x000a0;h<break/>Can be self-administered</td><td align="left">Acute attacks in adults and adolescents (investigated in patients aged &#x02265;13&#x000a0;years) with HAE</td><td char="." align="char">2014</td></tr></tbody></table><table-wrap-foot><p>
<italic>IV</italic> intravenous, <italic>rhC1-INH</italic> recombinant human C1 esterase inhibitor, <italic>SC</italic> subcutaneous</p></table-wrap-foot></table-wrap></p><p>This review provides comprehensive information on the synthesis, pharmacokinetics and pharmacodynamics, efficacy and safety of intravenous rhC1-INH for the treatment of patients with HAE. In addition, the product characteristics and safety profile of rhC1-INH are compared with those of human plasma-derived C1-INH products, ecallantide and icatibant. The articles included in this narrative review were identified by a systematic search of PubMed using (&#x0201c;recombinant c1 esterase inhibitor&#x0201d; OR &#x0201c;recombinant C1 inhibitor&#x0201d;) AND &#x0201c;hereditary angioedema&#x0201d; keywords for articles in English and consultation of recent review articles for general information on HAE prevalence, aetiology and treatment options. Bibliographies from included articles were reviewed manually for additional relevant studies.</p></sec><sec id="Sec2"><title>Clinical Pharmacology</title><sec id="Sec3"><title>Description</title><p>rhC1-INH, a single-chain glycoprotein of 478 amino acids, is derived from milk of transgenic rabbits (&#x0003e;99&#x000a0;% purity) using a 3-step Sepharose-based purification procedure including cation exchange chromatography, anion exchange chromatography and affinity chromatography [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The recombinant human formulation was developed as an alternative to human plasma-derived C1-INH to eliminate the risk of transmission of human blood-borne pathogens, as well as to provide a reliable and scalable supply that is not dependent on human plasma donors [<xref ref-type="bibr" rid="CR8">8</xref>]. It is approved in the European Union and the USA for adults and adolescents (evaluated in individuals &#x02265;13&#x000a0;years of age) for the treatment of acute angioedema attacks in patients with HAE due to C1-INH deficiency [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. The amino acid sequence of rhC1-INH is identical to that of endogenous human C1-INH but has differences in glycosylation patterns [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec4"><title>Pharmacokinetics and Pharmacodynamics</title><p>Population pharmacokinetics of rhC1-INH were evaluated by pooling data from six clinical studies in which blood samples were taken before and after intravenous administration of the drug in healthy volunteers, asymptomatic patients with HAE and patients with acute HAE attacks (294 administrations in 133 individuals; dose range 6.25&#x02013;121&#x000a0;U/kg) [<xref ref-type="bibr" rid="CR32">32</xref>]. In this analysis, the half-life of rhC1-INH was determined to be ~3&#x000a0;h for a 100&#x000a0;U/kg dose (similar to the mean half-life of 2.4&#x000a0;h reported for a 50&#x000a0;U/kg dose [<xref ref-type="bibr" rid="CR24">24</xref>]); this interval is shorter than the intervals reported for human plasma-derived C1-INH products, which range from 22 to 56&#x000a0;h [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]. A higher degree of glycosylation on the rhC1-INH protein results in faster clearance of rhC1-INH from the circulation compared with human plasma-derived C1-INH protein [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>The pharmacokinetic profile of rhC1-INH was similar after single and multiple dosing [<xref ref-type="bibr" rid="CR32">32</xref>]. The final estimation of the volume of distribution was 2.9&#x000a0;L, which is consistent with the reported volume of plasma [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Based on these analyses, a dosing scheme of 50&#x000a0;U/kg of rhC1-INH up to 84&#x000a0;kg body weight and a fixed dose of 4200 U for patients weighing &#x02265;84&#x000a0;kg (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR32">32</xref>] was deemed appropriate to restore functional C1-INH levels. In a separate pharmacokinetic study, 12 asymptomatic patients with HAE receiving 6.25&#x02013;100 U/kg of rhC1-INH on two occasions exhibited dose-dependent biological C1-INH activity with increasing plasma complement C4 levels (twofold after 12&#x000a0;h of administration of rhC1-INH 100&#x000a0;U/kg) and decreasing levels of its cleaved form [<xref ref-type="bibr" rid="CR31">31</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Simulation of peak recombinant human C1 esterase inhibitor (rhC1-INH) concentrations for levels of the proposed dosing regimen (50&#x000a0;U/kg for up to 84&#x000a0;kg body weight and a fixed dose of 4200&#x000a0;U for patients with body weight &#x0003e;84&#x000a0;kg). The 25th and 75th percentiles with the median values are represented as <italic>boxes</italic>; <italic>ends of whiskers</italic> represent 1.5 times the interquartile ranges (from the 25th and 75th quartiles). Any observations beyond 1.5 times the interquartile ranges are indicated as <italic>open circles</italic>, and the <italic>dashed line</italic> represents the lower limit of normal C1-INH (0.7&#x000a0;U/mL). Reprinted from Farrell et al. &#x000a9; 2013 The British Pharmacological Society [<xref ref-type="bibr" rid="CR32">32</xref>]</p></caption><graphic xlink:href="40261_2015_300_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec5"><title>Clinical Efficacy</title><sec id="Sec6"><title>Acute Attacks</title><p>The efficacy of rhC1-INH in the treatment of acute attacks in patients with HAE was evaluated in three randomized, double-blind, placebo-controlled studies and two open-label extension (OLE) studies (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. Two independent, randomized, double-blind, placebo-controlled studies were similarly designed: a North American study (C1 1205-01; 50 U/kg [<italic>n</italic>&#x000a0;=&#x000a0;12] or 100 U/kg [<italic>n</italic>&#x000a0;=&#x000a0;13] rhC1-INH vs placebo [<italic>n</italic>&#x000a0;=&#x000a0;13]) and a European study (C1 1304-01; 100 U/kg rhC1-INH [<italic>n</italic>&#x000a0;=&#x000a0;16] vs placebo [<italic>n</italic>&#x000a0;=&#x000a0;16]) [<xref ref-type="bibr" rid="CR36">36</xref>]. Patients included in these trials presented with onset of HAE symptoms within &#x0003c;5&#x000a0;h of enrolment and had an overall severity score of &#x02265;50&#x000a0;mm on a visual analogue scale (VAS) [<xref ref-type="bibr" rid="CR36">36</xref>]. The primary efficacy endpoint was the median time to onset of symptom relief (&#x02265;20&#x000a0;mm decrease from baseline in the VAS score for two consecutive readings) [<xref ref-type="bibr" rid="CR36">36</xref>]. A pooled analysis of the two studies indicated a significantly faster onset of symptom relief for both doses of rhC1-INH, 50 U/kg (122&#x000a0;min; 95&#x000a0;% confidence interval [CI] 72&#x02013;136; <italic>P</italic>&#x000a0;=&#x000a0;0.013) and 100&#x000a0;U/kg (66&#x000a0;min; 95&#x000a0;% CI 61&#x02013;122; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), versus placebo (495&#x000a0;min; 95&#x000a0;% CI 245&#x02013;520). Although the median time to onset of relief was different for 50 versus 100&#x000a0;U/kg in the pooled analysis, the 95&#x000a0;% CIs overlapped for these dosing regimens, and Kaplan&#x02013;Meier plots of both doses showed no significant difference in response. Median time to onset of relief at different anatomical locations (most attacks were peripheral or abdominal) with both doses of rhC1-INH (range 50&#x02013;124&#x000a0;min) was faster than with placebo (range 243&#x02013;560&#x000a0;min). In addition, treatment with both doses of rhC1-INH significantly reduced the median time to minimal symptoms compared with placebo (247, 266 and 1210&#x000a0;min for 50 and 100&#x000a0;U/kg rhC1-INH and placebo, respectively; <italic>P</italic>&#x000a0;&#x02264;&#x000a0;0.001 vs placebo for both rhC1-INH doses) [<xref ref-type="bibr" rid="CR36">36</xref>].<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Efficacy and safety of recombinant human C1 esterase inhibitor (rhC1-INH) for the treatment of hereditary angioedema (HAE) [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Phase</th><th align="left">Study design</th><th align="left">Population/dosing</th><th align="left">Efficacy results</th><th align="left">Safety</th></tr></thead><tbody><tr><td align="left" rowspan="2">C1 1205-01 (North American study) [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left" rowspan="2">2/3</td><td align="left">Randomized, double-blind, placebo-controlled</td><td align="left">38 patients with HAE; 38 HAE attacks<break/>50 U/kg rhC1-INH (<italic>n</italic>&#x000a0;=&#x000a0;12), 100 U/kg rhC1-INH (<italic>n</italic>&#x000a0;=&#x000a0;13) or placebo (<italic>n</italic>&#x000a0;=&#x000a0;13)</td><td align="left">Median time to onset of symptom relief (primary endpoint)<sup>a</sup>: 122, 68 and 258&#x000a0;min for 50 U/kg rhC1-INH, 100&#x000a0;U/kg rhC1-INH and placebo, respectively (50&#x000a0;mg, <italic>P</italic>&#x000a0;=&#x000a0;0.013 vs placebo); 66 and 495&#x000a0;min for 100 U/kg rhC1-INH and placebo, respectively (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) in pooled efficacy data from North American and European studies<break/>Median time to minimal symptoms<sup>b</sup>: 247, 245 and 1101&#x000a0;min with 50 and 100 U/kg rhC1-INH and placebo, respectively (50&#x000a0;mg, <italic>P</italic>&#x000a0;&#x02264;&#x000a0;0.001 vs placebo); 266 and 1210&#x000a0;min for 100 U/kg rhC1-INH and placebo, respectively (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) in pooled efficacy data from North American and European studies</td><td align="left">Pooled safety data from North American and European studies reported<break/>&#x02265;1 AE in 4&#x000a0;patients (33&#x000a0;%), 7&#x000a0;patients (24&#x000a0;%) and 14&#x000a0;patients (48&#x000a0;%) receiving 50 U and 100 U rhC1-INH and placebo, respectively<break/>Headache most common AE (10&#x000a0;%)<break/>1 patient (colitis) and 3&#x000a0;patients reported serious AEs in the rhC1-INH (100 U) and placebo groups, respectively (considered unrelated to the study drug)</td></tr><tr><td align="left">Open-label extension</td><td align="left">62 patients; 168 HAE attacks<break/>For 90 and 10&#x000a0;% of attacks, patients received 50 and 100 U/kg rhC1-INH, respectively</td><td align="left">Median time to onset of symptom relief for first 5 HAE attacks<sup>a</sup>: 37&#x02013;67&#x000a0;min<break/>Median time to minimal symptoms for first 5 HAE attacks<sup>b</sup>: 120&#x02013;244&#x000a0;min</td><td align="left">39 patients (63&#x000a0;%) reported &#x02265;1 AE<break/>Headache and nasopharyngitis most common AEs<break/>10 patients (14&#x000a0;%) reported serious AEs, of whom 8&#x000a0;patients reported HAE attacks; 7&#x000a0;serious AEs reported in 4&#x000a0;patients included vertigo, pneumonia, urosepsis occurring twice and itching of the lips and soft palate</td></tr><tr><td align="left" rowspan="2">C1 1304-01 (European study) [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left" rowspan="2">3</td><td align="left">Randomized, double-blind, placebo-controlled</td><td align="left">32 patients with HAE; for acute attacks<break/>100 U/kg rhC1-INH (<italic>n</italic>&#x000a0;=&#x000a0;16) or placebo (<italic>n</italic>&#x000a0;=&#x000a0;16)</td><td align="left">Median time to onset of symptom relief (primary endpoint)<sup>a</sup>: 64&#x000a0;min with 100 U/kg rhC1-INH and 520&#x000a0;min with placebo; 66 and 495&#x000a0;min for 100 U/kg rhC1-INH and placebo, respectively (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) in pooled efficacy data from North American and European studies<break/>Median time to minimal symptoms<sup>b</sup>: 480&#x000a0;min with 100 U/kg rhC1-INH and 1440&#x000a0;min with placebo; 266 and 1210&#x000a0;min for 100 U/kg rhC1-INH and placebo, respectively (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) in pooled efficacy data from North American and European studies</td><td align="left">Pooled safety data from North American and European studies reported (see safety data for North American study)</td></tr><tr><td align="left">Open-label extension</td><td align="left">57 patients; 194 attacks<break/>Vial-based dosing (2100 U) of rhC1-INH; 110, 68 and 15 attacks treated with 2100 U (1 vial), 4200 U (2 vials) and 6300 U (3 vials), respectively</td><td align="left">Median time to onset of symptom relief<sup>c</sup> for HAE attacks 1&#x02013;5: 60, 65, 120, 60 and 61&#x000a0;min, respectively<break/>Median time to minimal symptoms<sup>b</sup> showed consistent efficacy regardless of the number of attacks</td><td align="left">12 patients (28&#x000a0;%) and 9 patients (26&#x000a0;%) receiving 1 dose or &#x0003e;1 dose of rhC1-INH 2100 U, respectively, reported &#x02265;1 AE<break/>Headache and nausea were the most common AEs<break/>No serious AEs were reported</td></tr><tr><td align="left">C1 1310 [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">3</td><td align="left">Randomized, double-blind, placebo-controlled</td><td align="left">75 patients with HAE; for acute attacks<break/>50&#x000a0;U/kg for patients weighing &#x0003c;84&#x000a0;kg, 4200&#x000a0;U for patients weighing &#x02265;84&#x000a0;kg (<italic>n</italic>&#x000a0;=&#x000a0;44) or placebo (<italic>n</italic>&#x000a0;=&#x000a0;31)</td><td align="left">Median time to onset of symptom relief, based on TEQ score (primary endpoint)<sup>d</sup>: 90&#x000a0;min with rhC1-INH and 152&#x000a0;min with placebo (<italic>P</italic>&#x000a0;=&#x000a0;0.031)<break/>Median time to onset of symptom relief, based on VAS score<sup>c</sup>: 75&#x000a0;min with rhC1-INH and 303&#x000a0;min with placebo (<italic>P</italic>&#x000a0;=&#x000a0;0.003)<break/>Median time to minimal symptoms with rhC1-INH vs placebo: 303 vs 483&#x000a0;min, based on TEQ<sup>e</sup> score (<italic>P</italic>&#x000a0;=&#x000a0;0.078); 240 vs 362&#x000a0;min, based on VAS score<sup>b</sup> (<italic>P</italic>&#x000a0;=&#x000a0;0.005)</td><td align="left">&#x02265;1 AE reported in 4 patients (7&#x000a0;%) and 4 patients (22&#x000a0;%) in rhC1-INH and placebo groups, respectively, within 72&#x000a0;h postdose<break/>Most common AEs were respiratory, thoracic, mediastinal and gastrointestinal disorders<break/>1 serious AE (abdominal hernia) in rhC1-INH group &#x0003e;70&#x000a0;days postdose (considered unrelated to the study drug)</td></tr><tr><td align="left">C1 1207 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">2</td><td align="left">Open-label, prophylaxis</td><td align="left">25 patients with HAE<break/>Once-weekly administration of rhC1-INH 50 U/kg for 8&#x000a0;weeks</td><td align="left">Mean breakthrough attack rate was 0.4 attacks per week during 8-week period</td><td align="left">&#x02265;1 AE reported in 13 patients (52&#x000a0;%)<break/>4 AEs, mild in intensity, and considered possibly related to the study drug, were dry mouth, dizziness, hypotension and anxiety<break/>2 serious AEs were acute appendicitis and laryngeal oedema (considered unrelated to the study drug)</td></tr></tbody></table><table-wrap-foot><p>
<italic>AE</italic> adverse event, <italic>TEQ</italic> treatment effect questionnaire, <italic>VAS</italic> visual analogue scale</p><p>
<sup>a</sup>Interval until a &#x02265;20&#x000a0;mm decrease from baseline in VAS score for 2 consecutive recordings at any eligible location</p><p>
<sup>b</sup>Interval until VAS score decreased to &#x0003c;20&#x000a0;mm for all anatomical locations of an HAE attack</p><p>
<sup>c</sup>Interval until a &#x02265;20&#x000a0;mm decrease from baseline in VAS score at any eligible location</p><p>
<sup>d</sup>Based on a set of 3 questions to assess symptom severity (7-point categorical scale from &#x0201c;much worse&#x0201d; to &#x0201c;much better&#x0201d;)</p><p>
<sup>e</sup>Time between dosing and first time point at which patient reported a response of &#x0201c;yes&#x0201d; to TEQ question 3 (&#x0201c;At this moment, are your HAE attack symptoms minimal?&#x0201d;) for all attack locations</p></table-wrap-foot></table-wrap></p><p>The efficacy of rhC1-INH observed in the double-blind studies was maintained during treatment of subsequent HAE attacks during the OLE studies [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. For the first five HAE attacks during the North American OLE study (<italic>n</italic>&#x000a0;=&#x000a0;62), the median time to onset of symptom relief (&#x0003e;20&#x000a0;mm decrease from baseline in the VAS score) ranged from 37 to 67&#x000a0;min and the median time to minimal symptoms (VAS score &#x0003c;20&#x000a0;mm) ranged from 120 to 244&#x000a0;min [<xref ref-type="bibr" rid="CR37">37</xref>]. Few attacks (10.0&#x000a0;%) required treatment with a second dose, and of these, most were oro-facial-pharyngeal-laryngeal attacks. Like the North American OLE study, the European OLE study (<italic>n</italic>&#x000a0;=&#x000a0;57) supported the continued efficacy of rhC1-INH after repeated treatments for subsequent HAE attacks. The median times to onset of symptom relief (&#x02265;20&#x000a0;mm decrease from baseline in the VAS score) for HAE attack numbers 1 through 5 were 60, 65, 120, 60 and 61&#x000a0;min, respectively [<xref ref-type="bibr" rid="CR38">38</xref>]. By anatomical site, the fastest median time to symptomatic relief occurred with abdominal attacks (33&#x000a0;min), followed by peripheral attacks (61&#x000a0;min), oro-facial-pharyngeal-laryngeal attacks (120&#x000a0;min) and genitourinary attacks (480&#x000a0;min). The faster response observed with abdominal attacks compared with peripheral attacks is theorized to be due to faster resorption of fluid in the submucosal tissue compared with subcutaneous tissue.</p><p>In addition, a phase 3, randomized, double-blind, placebo-controlled study was conducted as part of an FDA biologics license application (Study C1 1310) [<xref ref-type="bibr" rid="CR39">39</xref>]. The study evaluated the efficacy and safety of rhC1-INH (50&#x000a0;U/kg for patients weighing &#x0003c;84&#x000a0;kg and 4200&#x000a0;U for patients weighing &#x02265;84&#x000a0;kg) for the treatment of acute attacks in patients with HAE. The most common primary attack locations (anatomical locations with the highest overall-severity baseline VAS scores) in this study were peripheral (44&#x000a0;%) and abdominal (37&#x000a0;%) [<xref ref-type="bibr" rid="CR39">39</xref>]. The primary endpoint, median time to onset of symptom relief, was significantly shorter in patients who received rhC1-INH compared with placebo, regardless of the instrument used to assess efficacy: the treatment effect questionnaire (TEQ) score (90 vs 152&#x000a0;min, respectively; <italic>P</italic>&#x000a0;=&#x000a0;0.031; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR39">39</xref>] or the VAS score (75 vs 303&#x000a0;min; <italic>P</italic>&#x000a0;=&#x000a0;0.003). Treatment with rhC1-INH also reduced the median time to minimal symptoms compared with placebo (303 vs 483&#x000a0;min, respectively [TEQ]; <italic>P</italic>&#x000a0;=&#x000a0;0.078; or 240 vs 362&#x000a0;min, respectively [VAS]; <italic>P</italic>&#x000a0;=&#x000a0;0.005).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Kaplan&#x02013;Meier plot of time to onset of symptom relief based on Treatment Effect Questionnaire results. In this phase 3, randomized, double-blind, placebo-controlled study, patients with an acute attack of hereditary angioedema were treated with recombinant human C1 esterase inhibitor (rhC1-INH) (50&#x000a0;U/kg for patients weighing &#x0003c;84&#x000a0;kg and 4200&#x000a0;U for patients weighing &#x02265;84&#x000a0;kg). The <italic>censor flags</italic> indicate time points at which data were censored: patients who did not achieve the beginning of persistent symptom relief during the 24-h assessment period were censored at the last assessment time point (i.e. excluded from further efficacy analyses). Patients who received prohibited medications or open-label rescue rhC1-1NH before perceiving persistent symptom relief were censored at the last time point at which the Treatment Effect Questionnaire score was assessed before these medications were administered. Patients who did not experience minimal symptoms during the assessment period also were censored at the last assessment time point. Reprinted from Riedl [<xref ref-type="bibr" rid="CR39">39</xref>], Copyright 2014, with permission from American College of Allergy, Asthma &#x00026; Immunology</p></caption><graphic xlink:href="40261_2015_300_Fig3_HTML" id="MO3"/></fig></p><p>Overall, the efficacy results from three randomized, double-blind, placebo-controlled studies and two OLE studies using a validated VAS instrument showed a consistent benefit of rhC1-INH in the treatment of acute angioedema attacks in patients with HAE [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. Although direct comparisons are not possible because of study design and outcome measure differences, the efficacy data for rhC1-INH in the treatment of acute attacks of HAE appear to be similar to results observed in randomized, placebo-controlled trials of human plasma-derived C1-INH products [<xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. The median times to onset of patient-reported symptom relief were 30&#x000a0;min with Berinert<sup>&#x000ae;</sup> 20&#x000a0;U/kg versus 90&#x000a0;min with placebo (<italic>P</italic>&#x000a0;=&#x000a0;0.0025) [<xref ref-type="bibr" rid="CR41">41</xref>] and 120&#x000a0;min with Cinryze<sup>&#x000ae;</sup> 1000&#x000a0;U versus &#x0003e;240&#x000a0;min with placebo (<italic>P</italic>&#x000a0;=&#x000a0;0.02) [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p>While not the focus of this review, it should be noted that the kinin pathway modulators ecallantide and icatibant are available as subcutaneous treatment options for acute HAE attacks. Ecallantide, a plasma kallikrein inhibitor, has been evaluated in two randomized, double-blind, placebo-controlled, phase 3 studies [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In one study (<italic>n</italic>&#x000a0;=&#x000a0;72), ecallantide 30&#x000a0;mg significantly reduced a composite treatment outcome score (range &#x02212;100 [significant symptom worsening] to +100 [significant symptom improvement]) at 4&#x000a0;h postdose versus placebo (median score 50.0 vs 0.0, respectively; <italic>P</italic>&#x000a0;=&#x000a0;0.004; primary endpoint) [<xref ref-type="bibr" rid="CR44">44</xref>]. There was no significant difference in the median time to significant improvement (patient-reported outcome of overall symptoms &#x0201c;a lot better or resolved&#x0201d;) between ecallantide (165.0&#x000a0;min) and placebo (&#x0003e;240&#x000a0;min; <italic>P</italic>&#x000a0;=&#x000a0;0.1). In a second study (<italic>n</italic>&#x000a0;=&#x000a0;96), a significant improvement from baseline in the mean symptom complex severity score (1&#x000a0;=&#x000a0;mild; 2&#x000a0;=&#x000a0;moderate; 3&#x000a0;=&#x000a0;severe) 4&#x000a0;h postdose was reported for ecallantide 30&#x000a0;mg (&#x02212;0.8&#x000a0;&#x000b1;&#x000a0;0.6) versus placebo (&#x02212;0.4&#x000a0;&#x000b1;&#x000a0;0.8; <italic>P</italic>&#x000a0;=&#x000a0;0.01; primary endpoint) [<xref ref-type="bibr" rid="CR45">45</xref>]. Ecallantide is licensed in the USA for the treatment of acute attacks of HAE in patients 12&#x000a0;years and older [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p>Icatibant, a bradykinin B<sub>2</sub> receptor antagonist, has been evaluated in three randomized, double-blind, phase 3 trials [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. One of the phase 3 studies (<italic>n</italic>&#x000a0;=&#x000a0;56) failed to meet the primary endpoint. No significant difference between subcutaneous icatibant 30&#x000a0;mg and placebo in the median time to clinically significant relief (&#x02265;30&#x000a0;% decrease from baseline in the VAS score; primary endpoint) of the index symptom was observed (2.5 vs 4.6&#x000a0;h, respectively; <italic>P</italic>&#x000a0;=&#x000a0;0.1), while in a second study (<italic>n</italic>&#x000a0;=&#x000a0;74) of icatibant 30&#x000a0;mg versus tranexamic acid 3&#x000a0;g/day, the same primary endpoint was achieved (2.0 vs 12.0, respectively; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) [<xref ref-type="bibr" rid="CR47">47</xref>]. Given the failure to achieve the primary endpoint in the first study, another placebo-controlled study (<italic>n</italic>&#x000a0;=&#x000a0;88) was conducted [<xref ref-type="bibr" rid="CR48">48</xref>]. In this third study, icatibant 30&#x000a0;mg significantly reduced the median time to cutaneous or abdominal attack symptom relief (50&#x000a0;% reduction from baseline in severity, assessed by a three-symptom [skin swelling, skin pain, abdominal pain] composite VAS score) versus placebo (2.0 vs 19.8&#x000a0;h; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001; primary endpoint). Icatibant is licensed in ~40 countries, including the USA, for the treatment of acute HAE attacks in patients 18&#x000a0;years and older [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec7"><title>Prophylaxis</title><p>The efficacy of rhC1-INH (50&#x000a0;U/kg once-weekly administration) for long-term prophylaxis in patients with HAE experiencing frequent attacks (&#x02265;1 attack every 2&#x000a0;weeks) was evaluated in a pilot open-label study (<italic>n</italic>&#x000a0;=&#x000a0;25) for 8&#x000a0;weeks (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR40">40</xref>]. The mean breakthrough attack rate was 0.4 attacks per week over the 8-week treatment period. Despite its short half-life, rhC1-INH appeared beneficial for long-term prophylaxis in patients with HAE. However, additional rigorous controlled studies are necessary to determine the true efficacy of rhC1-INH for long-term HAE prophylaxis [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Both human plasma-derived C1-INH products have been used for short-term and long-term prophylaxis in HAE as reported in uncontrolled and observational studies [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. In addition, in a randomized, double-blind, placebo-controlled, crossover study (<italic>n</italic>&#x000a0;=&#x000a0;22) in which Cinryze<sup>&#x000ae;</sup> 1000&#x000a0;U or placebo was administered every 3&#x02013;4&#x000a0;days for 12&#x000a0;weeks, with open-label Cinryze<sup>&#x000ae;</sup> as rescue treatment for acute attacks, the frequency of HAE attacks was reduced by ~50&#x000a0;% during Cinryze<sup>&#x000ae;</sup> versus placebo administration [<xref ref-type="bibr" rid="CR42">42</xref>]. Currently, in the USA, Cinryze<sup>&#x000ae;</sup> is the only C1-INH agent approved for the routine prophylaxis of HAE attacks. A 12-week, dose-escalation study in 2014 indicated that some patients may require up to 2500&#x000a0;U of Cinryze<sup>&#x000ae;</sup> every 3&#x02013;4&#x000a0;days to prevent acute HAE attacks [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec></sec><sec id="Sec8"><title>Safety and Tolerability</title><sec id="Sec9"><title>Adverse Events</title><p>Safety data from randomized, controlled studies and OLE studies with rhC1-INH (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) support a favourable safety profile [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>], and results were similar to those reported in clinical trials of human plasma-derived C1-INH products [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Pooled safety data from the two randomized, placebo-controlled studies indicated that 33, 24 and 48&#x000a0;% of patients receiving 50&#x000a0;U/kg rhC1-INH, 100&#x000a0;U/kg rhC1-INH and placebo, respectively, had &#x02265;1 adverse event (AE) [<xref ref-type="bibr" rid="CR36">36</xref>]. Headache was the most common AE in the rhC1-INH 100&#x000a0;U/kg group (10&#x000a0;%) and the placebo group (14&#x000a0;%); no headaches were reported in the 50&#x000a0;U/kg group. Headache and vertigo were considered related to rhC1-INH treatment. Colitis was reported in one patient after 31&#x000a0;days of rhC1-INH 100&#x000a0;U/kg treatment; it was not considered by the investigators to be related to the study drug and was the only serious AE reported in the rhC1-INH groups. In an additional phase 3, randomized, controlled study, 7 and 22&#x000a0;% of patients reported &#x02265;1 AE in the rhC1-INH and placebo groups, respectively, within 72&#x000a0;h of dosing; one serious AE of abdominal hernia in the rhC1-INH group after 70&#x000a0;days of dosing was considered unrelated to the study drug [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p>Safety data reported in the OLE studies were generally similar to those reported in the randomized controlled studies. In the North American OLE study, 63&#x000a0;% of patients reported &#x02265;1 AE, and most AEs were mild to moderate in intensity [<xref ref-type="bibr" rid="CR37">37</xref>]. Twenty serious AEs were reported in ten patients, of which 13 AEs in eight patients were HAE attacks; seven serious AEs reported in four patients included vertigo, pneumonia, urosepsis (two episodes) and itching of the lips and soft palate with no signs of a systemic allergic reaction. In the European OLE study, additional dose(s) of rhC1-INH administered in a subset of patients did not increase the incidence of AEs (28 and 26&#x000a0;% of patients receiving one dose or &#x02265;1 dose of rhC1-INH 2100 U, respectively), and no serious AEs were reported in this study [<xref ref-type="bibr" rid="CR38">38</xref>]. In the long-term prophylaxis study with rhC1-INH, 52&#x000a0;% of patients reported &#x02265;1 AE; two AEs (acute appendicitis and laryngeal oedema) were serious, but neither was considered related to the study drug [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>An increased risk of thromboembolic complications has been reported with off-label, high-dose use of human plasma-derived C1-INH products, potentially mediated through increased levels of C1-INH, which can interact with fibrinolytic proteases, leading to a risk of thromboembolic adverse effects [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. However, clinical studies with rhC1-INH have not suggested an increased risk of thromboembolic complications [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. Post hoc analyses of the effects of rhC1-INH on coagulation and fibrinolysis in patients with HAE who participated in the randomized, placebo-controlled North American study further supported that rhC1-INH treatment had no prothrombotic effects in patients with HAE receiving up to 100 U/kg [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</p><p>Regarding the safety and tolerability profile of other acute HAE therapies, the most common AEs reported for ecallantide (<italic>n</italic>&#x000a0;=&#x000a0;255; pooled data) were headache (16&#x000a0;%), nausea (13&#x000a0;%), fatigue (12&#x000a0;%) and diarrhoea (11&#x000a0;%) [<xref ref-type="bibr" rid="CR22">22</xref>]. Anaphylaxis has been reported in 4.0&#x000a0;% of patients treated with ecallantide; thus, a boxed warning in the prescribing information indicates that ecallantide should only be administered by a healthcare provider with appropriate support to manage cases of anaphylaxis, and that patients should be closely monitored due to the similarity between symptoms of hypersensitivity reaction and an HAE attack [<xref ref-type="bibr" rid="CR22">22</xref>]. Unlike with ecallantide, no events of anaphylaxis have been reported in clinical trials of icatibant [<xref ref-type="bibr" rid="CR23">23</xref>]. The most commonly reported AEs with icatibant (<italic>n</italic>&#x000a0;=&#x000a0;77; pooled data) have been injection-site reactions (97&#x000a0;%), pyrexia (4&#x000a0;%) and increased transaminase levels (4&#x000a0;%) [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec10"><title>Immunogenicity</title><p>Therapeutic proteins have the risk of eliciting an antibody response to the protein itself (anti-drug antibodies) or to impurities originating from the biological system used to produce the protein (e.g. anti-host-related impurities [anti-HRI]) [<xref ref-type="bibr" rid="CR52">52</xref>]. Because rhC1-INH is derived from the milk of transgenic rabbits and contains a small percentage (&#x0003c;0.002&#x000a0;%) of HRI, it is contraindicated in patients with known or suspected allergy to rabbits or rabbit-derived products [<xref ref-type="bibr" rid="CR24">24</xref>]. Data from clinical trials support that rhC1-INH has a low potential to induce anti-drug antibodies or anti-HRI responses in patients with HAE [<xref ref-type="bibr" rid="CR52">52</xref>]. In a pooled analysis of five rhC1-INH clinical studies in symptomatic patients with HAE (<italic>n</italic>&#x000a0;=&#x000a0;155; 424 administrations), 1.5 and 1.3&#x000a0;% of all pre-exposure and postexposure tests, respectively, were above the cutoff level (set using plasma samples from &#x02265;50 patients with HAE na&#x000ef;ve to rhC1-INH) of the screening assays for anti-C1-INH antibodies. However, these results were not accompanied by any clinical symptoms indicating hypersensitivity or any apparent changes in rhC1-INH efficacy. Anti-HRI antibodies were above the cutoff level in 0.7, 1.9 and 1.6&#x02013;3.1&#x000a0;% of the screening assay tests before exposure, at 90&#x000a0;days after the first exposure and after repeat rhC1-INH treatment (22 or 90&#x000a0;days after repeat exposure), respectively. As with the anti-C1-INH antibody results, positive anti-HRI antibody results were not accompanied by clinical symptoms of hypersensitivity reactions.</p><p>The potential of rhC1-INH to induce immunoglobulin E (IgE) antibodies against rabbit milk proteins and other allergens was tested by a retrospective analysis of eight rhC1-INH clinical studies (130 patients with HAE and 14 healthy volunteers; 300 administrations) [<xref ref-type="bibr" rid="CR53">53</xref>]. Approximately 50&#x000a0;% of individuals were exposed more than once to rhC1INH (median, 2). A total of 24 individuals tested positive for select animal allergens (e.g. rabbit, cow, cat or horse dander) prior to rhC1-INH exposure. Five of these individuals had pre-existing anti-rabbit-epithelium IgE antibodies, and one of them experienced an anaphylactic reaction, the only such case observed in this study population. This individual received antihistamine and inhaled &#x003b2;-agonist therapy, with normalization of her condition within 1&#x000a0;h. None of these individuals had an increase in anti-rabbit IgE levels after rhC1-INH exposure. Of the 19 of 24 individuals who had pre-exposure positivity for select animal allergens other than rabbit, three (15.8&#x000a0;%) developed anti-rabbit IgE antibodies after rhC1-INH exposure; none of these individuals experienced allergic-type reactions during treatment with rhC1-INH.</p></sec></sec><sec id="Sec11" sec-type="conclusion"><title>Conclusions</title><p>HAE is a rare genetic disorder caused by a deficiency in functional C1-INH, and rapid replacement of functional C1-INH is a treatment strategy for managing HAE attacks. The recombinant technology used for the production of rhC1-INH addresses plasma supply concerns and potential risks for transmissible infections associated with human plasma-derived C1-INH products. Global, multicentre clinical studies have demonstrated that rhC1-INH is efficacious and well tolerated for the treatment of acute HAE attacks. Treatment with rhC1-INH has been shown to produce a rapid and sustained improvement in attack-related clinical symptoms. Preliminary data also suggest that rhC1-INH may be beneficial as long-term prophylaxis in patients with HAE; however, additional controlled studies are needed to validate this finding. A phase 2 prophylaxis study is ongoing, with anticipated completion in 2015. Currently, the clinical management of HAE involves individualized patient treatment plans using licensed medication options to terminate attacks, with additional prophylactic therapy in selected patients. The rapid onset of relief, durable efficacy and favourable safety profile associated with rhC1-INH treatment support its use in acute HAE treatment plans.</p></sec></body><back><ack><title>Declaration of funding/acknowledgments</title><p>The author was not provided funding for development of this review. Technical editorial and medical writing assistance was provided by Mary Beth Moncrief, PhD, and Pratibha Hebbar, PhD, of Synchrony Medical Communications, LLC (West Chester, PA, USA). Funding for this support was provided by Salix, a Division of Valeant Pharmaceuticals North America LLC (Bridgewater, NJ, USA).</p><sec id="d30e1390"><title>Disclosures</title><p>MR reports being a scientific consultant for Biocryst, CSL Behring, Dyax, Isis Pharmaceuticals, Inc., Santarus (previously a wholly owned subsidiary of Salix), Shire and ViroPharma, Inc.; and receiving research funding from Biocryst, CSL Behring, Dyax, Pharming, Shire and ViroPharma.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>BL</given-names></name></person-group><article-title>Clinical practice: hereditary angioedema</article-title><source>N Engl J Med.</source><year>2008</year><volume>359</volume><issue>10</issue><fpage>1027</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1056/NEJMcp0803977</pub-id><pub-id pub-id-type="pmid">18768946</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardarelli</surname><given-names>W</given-names></name></person-group><article-title>Managed care implications of hereditary angioedema</article-title><source>Am J Manag Care.</source><year>2013</year><volume>19</volume><issue>7 Suppl</issue><fpage>s119</fpage><lpage>s124</lpage><pub-id pub-id-type="pmid">23844784</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lumry</surname><given-names>WR</given-names></name><name><surname>Castaldo</surname><given-names>AJ</given-names></name><name><surname>Vernon</surname><given-names>MK</given-names></name><etal/></person-group><article-title>The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression</article-title><source>Allergy Asthma Proc.</source><year>2010</year><volume>31</volume><issue>5</issue><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.2500/aap.2010.31.3394</pub-id><pub-id pub-id-type="pmid">20929608</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>T</given-names></name><name><surname>Ayg&#x000f6;ren-P&#x000fc;rs&#x000fc;n</surname><given-names>E</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><etal/></person-group><article-title>WAO guideline for the management of hereditary angioedema</article-title><source>World Allergy Organ J.</source><year>2012</year><volume>5</volume><issue>12</issue><fpage>182</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1097/WOX.0b013e318279affa</pub-id><pub-id pub-id-type="pmid">23282420</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bygum</surname><given-names>A</given-names></name></person-group><article-title>Hereditary angio-oedema in Denmark: a nationwide survey</article-title><source>Br J Dermatol.</source><year>2009</year><volume>161</volume><issue>5</issue><fpage>1153</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2009.09366.x</pub-id><pub-id pub-id-type="pmid">19709101</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roche</surname><given-names>O</given-names></name><name><surname>Blanch</surname><given-names>A</given-names></name><name><surname>Caballero</surname><given-names>T</given-names></name><etal/></person-group><article-title>Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain</article-title><source>Ann Allergy Asthma Immunol.</source><year>2005</year><volume>94</volume><issue>4</issue><fpage>498</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/S1081-1206(10)61121-0</pub-id><pub-id pub-id-type="pmid">15875532</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gompels</surname><given-names>MM</given-names></name><name><surname>Lock</surname><given-names>RJ</given-names></name><name><surname>Abinun</surname><given-names>M</given-names></name><etal/></person-group><article-title>C1 inhibitor deficiency: consensus document</article-title><source>Clin Exp Immunol.</source><year>2005</year><volume>139</volume><issue>3</issue><fpage>379</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2005.02726.x</pub-id><pub-id pub-id-type="pmid">15730382</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamaukhova</surname><given-names>E</given-names></name></person-group><article-title>C1-esterase inhibitor: biological activities and therapeutic applications</article-title><source>J Hematol Thromb.</source><year>2013</year></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>RB</given-names></name><name><surname>Reboul</surname><given-names>A</given-names></name><name><surname>Arlaud</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Interaction of <sup>125</sup>I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma</article-title><source>FEBS Lett.</source><year>1979</year><volume>97</volume><issue>1</issue><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(79)80063-0</pub-id><pub-id pub-id-type="pmid">761607</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziccardi</surname><given-names>RJ</given-names></name></person-group><article-title>Activation of the early components of the classical complement pathway under physiologic conditions</article-title><source>J Immunol.</source><year>1981</year><volume>126</volume><issue>5</issue><fpage>1769</fpage><lpage>1773</lpage><pub-id pub-id-type="pmid">7217665</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Agostini</surname><given-names>A</given-names></name><name><surname>Lijnen</surname><given-names>HR</given-names></name><name><surname>Pixley</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor</article-title><source>J Clin Invest.</source><year>1984</year><volume>73</volume><issue>6</issue><fpage>1542</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1172/JCI111360</pub-id><pub-id pub-id-type="pmid">6725552</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schapira</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>CF</given-names></name><name><surname>Colman</surname><given-names>RW</given-names></name></person-group><article-title>Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma</article-title><source>J Clin Invest.</source><year>1982</year><volume>69</volume><issue>2</issue><fpage>462</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1172/JCI110470</pub-id><pub-id pub-id-type="pmid">6173399</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huisman</surname><given-names>LG</given-names></name><name><surname>van Griensven</surname><given-names>JM</given-names></name><name><surname>Kluft</surname><given-names>C</given-names></name></person-group><article-title>On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma</article-title><source>Thromb Haemost.</source><year>1995</year><volume>73</volume><issue>3</issue><fpage>466</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">7667830</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wuillemin</surname><given-names>WA</given-names></name><name><surname>Minnema</surname><given-names>M</given-names></name><name><surname>Meijers</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor</article-title><source>Blood.</source><year>1995</year><volume>85</volume><issue>6</issue><fpage>1517</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">7534133</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rkqvist</surname><given-names>J</given-names></name><name><surname>Sala-Cunill</surname><given-names>A</given-names></name><name><surname>Renne</surname><given-names>T</given-names></name></person-group><article-title>Hereditary angioedema: a bradykinin-mediated swelling disorder</article-title><source>Thromb Haemost.</source><year>2013</year><volume>109</volume><issue>3</issue><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1160/TH12-08-0549</pub-id><pub-id pub-id-type="pmid">23306453</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nussberger</surname><given-names>J</given-names></name><name><surname>Cugno</surname><given-names>M</given-names></name><name><surname>Amstutz</surname><given-names>C</given-names></name><etal/></person-group><article-title>Plasma bradykinin in angio-oedema</article-title><source>Lancet.</source><year>1998</year><volume>351</volume><issue>9117</issue><fpage>1693</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(97)09137-X</pub-id><pub-id pub-id-type="pmid">9734886</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>FS</given-names></name><name><surname>Pensky</surname><given-names>J</given-names></name><name><surname>Donaldson</surname><given-names>V</given-names></name><etal/></person-group><article-title>Hereditary angioneurotic edema: two genetic variants</article-title><source>Science.</source><year>1965</year><volume>148</volume><issue>3672</issue><fpage>957</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1126/science.148.3672.957</pub-id><pub-id pub-id-type="pmid">14277836</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>BL</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Lang</surname><given-names>DM</given-names></name><etal/></person-group><article-title>A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema</article-title><source>J Allergy Clin Immunol.</source><year>2013</year><volume>131</volume><issue>6</issue><fpage>1491</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.03.034</pub-id><pub-id pub-id-type="pmid">23726531</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Caballero</surname><given-names>T</given-names></name><collab>On behalf of HAWK (Hereditary Angioedema International Working Group)</collab><etal/></person-group><article-title>Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an international working group</article-title><source>Allergy</source><year>2012</year><volume>67</volume><issue>2</issue><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2011.02751.x</pub-id><pub-id pub-id-type="pmid">22126399</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Cinryze<sup><bold>&#x000ae;</bold></sup> (c1 esterase inhibitor [human]) [package insert]. Exton: ViroPharma Biologics, Inc., 2012.</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Berinert<sup><bold>&#x000ae;</bold></sup> [C1 esterase inhibitor (human)] [package insert]. Marburg: CSL Behring GmbH; 2012.</mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Kalbitor<sup><bold>&#x000ae;</bold></sup> (ecallantide) injection, for subcutaneous use [package insert]. Burlington: Dyax Corp.; 2012.</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Firazyr<sup><bold>&#x000ae;</bold></sup> (icatibant) injection, for subcutaneous use [package insert]. Lexington: Shire Orphan Therapies, Inc.; 2011.</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Ruconest<sup>&#x000ae;</sup> (C1 esterase inhibitor [recombinant]) for intravenous use, lyophilized powder for reconstitution [package insert]. Raleigh: Salix Pharmaceuticals, Inc.; 2014.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name></person-group><article-title>Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema</article-title><source>Immunotherapy.</source><year>2014</year><volume>6</volume><issue>5</issue><fpage>533</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.2217/imt.14.33</pub-id><pub-id pub-id-type="pmid">24635050</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Danocrine<sup>&#x000ae;</sup> [package insert]. Bridgewater: Sanofi-Aventis US LLC; 2011.</mixed-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>YY</given-names></name><name><surname>Buyantseva</surname><given-names>LV</given-names></name><name><surname>Agarwal</surname><given-names>NS</given-names></name><etal/></person-group><article-title>Update on treatment of hereditary angioedema</article-title><source>Clin Exp Allergy.</source><year>2013</year><volume>43</volume><issue>4</issue><fpage>395</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1111/cea.12080</pub-id><pub-id pub-id-type="pmid">23517035</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Firazyr<sup><bold>&#x000ae;</bold></sup> 30&#x000a0;mg solution for injection in pre-filled syringe [package insert]. Berlin: Shire Orphan Therapies GmbH; 2013.</mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Ruconest<sup><bold>&#x000ae;</bold></sup> 2100&#x000a0;U powder for solution for injection [package insert]. Leiden: Pharming Group NV; 2010.</mixed-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Veen</surname><given-names>HA</given-names></name><name><surname>Koiter</surname><given-names>J</given-names></name><name><surname>Vogelezang</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits</article-title><source>J Biotechnol.</source><year>2012</year><volume>162</volume><issue>2&#x02013;3</issue><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2012.09.005</pub-id><pub-id pub-id-type="pmid">22995741</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doorn</surname><given-names>MB</given-names></name><name><surname>Burggraaf</surname><given-names>J</given-names></name><name><surname>van Dam</surname><given-names>T</given-names></name><etal/></person-group><article-title>A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema</article-title><source>J Allergy Clin Immunol.</source><year>2005</year><volume>116</volume><issue>4</issue><fpage>876</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2005.05.019</pub-id><pub-id pub-id-type="pmid">16210064</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>C</given-names></name><name><surname>Hayes</surname><given-names>S</given-names></name><name><surname>Relan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema</article-title><source>Br J Clin Pharmacol.</source><year>2013</year><volume>76</volume><issue>6</issue><fpage>897</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1111/bcp.12132</pub-id><pub-id pub-id-type="pmid">23594263</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Saguer</surname><given-names>I</given-names></name><name><surname>Rusicke</surname><given-names>E</given-names></name><name><surname>Ayg&#x000f6;ren-P&#x000fc;rs&#x000fc;n</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study</article-title><source>Transfusion.</source><year>2010</year><volume>50</volume><issue>2</issue><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2009.02394.x</pub-id><pub-id pub-id-type="pmid">19788511</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Ritchie</surname><given-names>B</given-names></name><name><surname>Levy</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks</article-title><source>Ann Allergy Asthma Immunol.</source><year>2010</year><volume>105</volume><issue>2</issue><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2010.06.005</pub-id><pub-id pub-id-type="pmid">20674826</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>TC</given-names></name><name><surname>Guthrie</surname><given-names>DL</given-names></name><name><surname>Simpson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the International Council for Standardization in Haematology</article-title><source>Br J Haematol.</source><year>1995</year><volume>89</volume><issue>4</issue><fpage>748</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.1995.tb08411.x</pub-id><pub-id pub-id-type="pmid">7772511</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>B</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema</article-title><source>J Allergy Clin Immunol.</source><year>2010</year><volume>126</volume><issue>4</issue><fpage>821</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2010.07.021</pub-id><pub-id pub-id-type="pmid">20920772</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedl</surname><given-names>MA</given-names></name><name><surname>Levy</surname><given-names>RJ</given-names></name><name><surname>Suez</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study</article-title><source>Ann Allergy Asthma Immunol.</source><year>2013</year><volume>110</volume><issue>4</issue><fpage>295</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2013.02.007</pub-id><pub-id pub-id-type="pmid">23535096</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moldovan</surname><given-names>D</given-names></name><name><surname>Reshef</surname><given-names>A</given-names></name><name><surname>Fabiani</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study</article-title><source>Clin Exp Allergy.</source><year>2012</year><volume>42</volume><issue>6</issue><fpage>929</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">22909164</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedl</surname><given-names>MA</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial</article-title><source>Ann Allergy Asthma Immunol.</source><year>2014</year><volume>112</volume><issue>2</issue><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2013.12.004</pub-id><pub-id pub-id-type="pmid">24468257</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reshef</surname><given-names>A</given-names></name><name><surname>Moldovan</surname><given-names>D</given-names></name><name><surname>Obtulowicz</surname><given-names>K</given-names></name><etal/></person-group><article-title>Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study</article-title><source>Allergy.</source><year>2013</year><volume>68</volume><issue>1</issue><fpage>118</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1111/all.12060</pub-id><pub-id pub-id-type="pmid">23121116</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>TJ</given-names></name><name><surname>Levy</surname><given-names>RJ</given-names></name><name><surname>Wasserman</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks</article-title><source>J Allergy Clin Immunol.</source><year>2009</year><volume>124</volume><issue>4</issue><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.07.017</pub-id><pub-id pub-id-type="pmid">19767078</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>BL</given-names></name><name><surname>Busse</surname><given-names>PJ</given-names></name><name><surname>White</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema</article-title><source>N Engl J Med.</source><year>2010</year><volume>363</volume><issue>6</issue><fpage>513</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0805538</pub-id><pub-id pub-id-type="pmid">20818886</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawalec</surname><given-names>P</given-names></name><name><surname>Holko</surname><given-names>P</given-names></name><name><surname>Paszulewicz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results</article-title><source>Pneumonol Alergol Pol</source><year>2013</year><volume>81</volume><issue>2</issue><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">23420425</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>RJ</given-names></name><name><surname>McNeil</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Ecallantide for the treatment of acute attacks in hereditary angioedema</article-title><source>N Engl J Med.</source><year>2010</year><volume>363</volume><issue>6</issue><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0905079</pub-id><pub-id pub-id-type="pmid">20818887</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>RJ</given-names></name><name><surname>Lumry</surname><given-names>WR</given-names></name><name><surname>McNeil</surname><given-names>DL</given-names></name><etal/></person-group><article-title>EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema</article-title><source>Ann Allergy Asthma Immunol.</source><year>2010</year><volume>104</volume><issue>6</issue><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2010.04.012</pub-id><pub-id pub-id-type="pmid">20568386</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Kalbitor<sup>&#x000ae;</sup> (ecallantide) injection, for subcutaneous use [package insert]. Burlington: Dyax Corp.; 2014.</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Banerji</surname><given-names>A</given-names></name><name><surname>Bracho</surname><given-names>F</given-names></name><etal/></person-group><article-title>Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema</article-title><source>N Engl J Med.</source><year>2010</year><volume>363</volume><issue>6</issue><fpage>532</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0906393</pub-id><pub-id pub-id-type="pmid">20818888</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lumry</surname><given-names>WR</given-names></name><name><surname>Li</surname><given-names>HH</given-names></name><name><surname>Levy</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial</article-title><source>Ann Allergy Asthma Immunol.</source><year>2011</year><volume>107</volume><issue>6</issue><fpage>529</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2011.08.015</pub-id><pub-id pub-id-type="pmid">22123383</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Manning</surname><given-names>ME</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Escalating doses of C1 esterase inhibitor (Cinryze) for prophylaxis in patients with hereditary angioedema</article-title><source>J Allergy Clin Immunol Pract.</source><year>2014</year><volume>2</volume><issue>1</issue><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2013.09.008</pub-id><pub-id pub-id-type="pmid">24565773</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>PK</given-names></name><name><surname>Gentry</surname><given-names>WM</given-names></name><name><surname>Bottorff</surname><given-names>MB</given-names></name></person-group><article-title>Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration Adverse Event Reporting System database</article-title><source>Pharmacotherapy.</source><year>2012</year><volume>32</volume><issue>10</issue><fpage>902</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1002/j.1875-9114.2012.01126</pub-id><pub-id pub-id-type="pmid">23033229</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Relan</surname><given-names>A</given-names></name><name><surname>Bakhtiari</surname><given-names>K</given-names></name><name><surname>van Amersfoort</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema</article-title><source>BioDrugs.</source><year>2012</year><volume>26</volume><issue>1</issue><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.2165/11599490-000000000-00000</pub-id><pub-id pub-id-type="pmid">22171564</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Mannesse</surname><given-names>M</given-names></name><name><surname>Baboeram</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies</article-title><source>BioDrugs.</source><year>2012</year><volume>26</volume><issue>5</issue><fpage>303</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1007/BF03261888</pub-id><pub-id pub-id-type="pmid">22928662</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Relan</surname><given-names>A</given-names></name><name><surname>Baboeram</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of IgE antibodies</article-title><source>Clin Drug Investig.</source><year>2013</year><volume>33</volume><issue>4</issue><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1007/s40261-013-0064-2</pub-id><pub-id pub-id-type="pmid">23463274</pub-id></element-citation></ref></ref-list></back></article>